Promoter Polymorphisms of DNA Methyltransferase 3B and Risk of Hepatocellular Carcinoma

Overview

Journal Biomed Rep

Specialty Biochemistry

Date 2014 Mar 21

PMID 24649027

Citations 11

Authors

Yingbin Lao

Huazhang Wu

Chengchegn Zhao

Qunying Wu

Fengchang Qiao

Hong Fan

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is one of the most common solid tumors worldwide. Epigenetic changes in gene expression, including DNA methylation and histone modifications, may contribute to the development of HCC. Polymorphisms of the gene may affect the activity of this enzyme and increase the susceptibility to several types of cancer, including HCC. To confirm this hypothesis, we investigated the association between single-nucleotide polymorphisms-149C>T (rs2424913) and -579G>T (rs1569686) in the promoter region of DNMT3B and the risk of HCC. single-nucleotide polymorphisms (SNPs) were genotyped by polymerase chain reaction-restriction fragment length polymorphism in 108 HCC patients and 240 healthy controls matched for age, gender and ethnicity. The DNMT3B-149 TT genotype was not significantly associated with an increased risk of HCC. The frequency of DNMT3B-149C was 0.46% in HCC patients and 1.39% in healthy individuals, whereas the frequency of DNMT3B-579G was 8.33% in HCC patients and 10.42% in healthy individuals. No significant differences were observed in the genotype or allelic distribution between HCC patients and controls. In conclusion, DNMT3B-149C>T and -579G>T polymorphisms are not significantly associated with an increased risk of HCC. These results demonstrated that these particular SNPs may not be used as biomarkers to predict susceptibility to HCC.

Citing Articles

Downregulating DNA methyltransferase 3B by suppressing the PI3K/Akt signaling pathway enhances the chemosensitivity of glioblastoma to temozolomide.

Kan W, Gao L, Chen J, Chen L, Zhang G, Hao B Mol Neurobiol. 2024; 61(9):7066-7074.

PMID: 38368287 PMC: 11339175. DOI: 10.1007/s12035-024-04041-7.

Investigation of the DNMT3B -579 G>T Promoter Polymorphism in Patients with Colorectal Cancer in an Azerbaijani Population.

Bayramov B, Bayramov N, Aslanov H, Abbasov M, Mammadova S, Eynullazada K Asian Pac J Cancer Prev. 2022; 23(6):1879-1884.

PMID: 35763627 PMC: 9587849. DOI: 10.31557/APJCP.2022.23.6.1879.

Meta-analysis Reveals No Association of DNMT3B -149 C>T Gene Polymorphism With Overall Cancer Risk.

Mandal R, Haque S, Wahid M, Jawed A, Akhter N, Khan M Curr Genomics. 2017; 17(6):528-537.

PMID: 28217009 PMC: 5282604. DOI: 10.2174/1389202917666160530150036.

Associations of DNMT3B -149C>T and -2437T>A polymorphisms and lung cancer risk in Chinese population.

Gao M, He D, Meng F, Li J, Shen Y World J Surg Oncol. 2016; 14(1):293.

PMID: 27876061 PMC: 5118893. DOI: 10.1186/s12957-016-1052-9.

New insights on the role of epigenetic alterations in hepatocellular carcinoma.

Frau M, Feo C, Feo F, Pascale R J Hepatocell Carcinoma. 2016; 1:65-83.

PMID: 27508177 PMC: 4918272. DOI: 10.2147/JHC.S44506.

References

Wang Z, Cao Y, Jiang C, Yang G, Wu J, Ding Y . Lack of association of two common polymorphisms rs2910164 and rs11614913 with susceptibility to hepatocellular carcinoma: a meta-analysis. PLoS One. 2012; 7(6):e40039. PMC: 3386926. DOI: 10.1371/journal.pone.0040039. View

Figueroa M, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos P . DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010; 17(1):13-27. PMC: 3008568. DOI: 10.1016/j.ccr.2009.11.020. View

Egger G, Liang G, Aparicio A, Jones P . Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004; 429(6990):457-63. DOI: 10.1038/nature02625. View

Deng G, Zhou G, Zhang R, Zhai Y, Zhao W, Yan Z . Regulatory polymorphisms in the promoter of CXCL10 gene and disease progression in male hepatitis B virus carriers. Gastroenterology. 2008; 134(3):716-26. DOI: 10.1053/j.gastro.2007.12.044. View

Noushmehr H, Weisenberger D, Diefes K, Phillips H, Pujara K, Berman B . Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010; 17(5):510-22. PMC: 2872684. DOI: 10.1016/j.ccr.2010.03.017. View

Wjst M . Target SNP selection in complex disease association studies. BMC Bioinformatics. 2004; 5:92. PMC: 487897. DOI: 10.1186/1471-2105-5-92. View

Chen C, Chen D . Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: multistage hepatocarcinogenesis with multifactorial etiology. Hepatology. 2002; 36(5):1046-9. DOI: 10.1053/jhep.2002.37084. View

Paz M, Fraga M, Avila S, Guo M, Pollan M, Herman J . A systematic profile of DNA methylation in human cancer cell lines. Cancer Res. 2003; 63(5):1114-21. View

Zhang H, Zhai Y, Hu Z, Wu C, Qian J, Jia W . Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet. 2010; 42(9):755-8. DOI: 10.1038/ng.638. View

10.

Fang C, Sun W, Han H, Shi L, Wang L, Zhao Y . The -149C>T polymorphism of DNMT3B is not associated with colorectal cancer risk: Evidence from a meta-analysis based on case-control studies. Exp Ther Med. 2012; 4(4):728-732. PMC: 3501434. DOI: 10.3892/etm.2012.638. View

11.

Wang L, Rodriguez M, Kim E, Xu Y, Bekele N, El-Naggar A . A novel C/T polymorphism in the core promoter of human de novo cytosine DNA methyltransferase 3B6 is associated with prognosis in head and neck cancer. Int J Oncol. 2004; 25(4):993-9. View

12.

Zhao H, Du W, Gu D, Wang D, Xue F, Ge J . DNMT3B 579G>T promoter polymorphism and the risk for idiopathic thrombocytopenic purpura in a Chinese population. Acta Haematol. 2009; 122(1):31-5. DOI: 10.1159/000235616. View

13.

Miller S, Dykes D, Polesky H . A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16(3):1215. PMC: 334765. DOI: 10.1093/nar/16.3.1215. View

14.

Esteller M . Epigenetics in cancer. N Engl J Med. 2008; 358(11):1148-59. DOI: 10.1056/NEJMra072067. View

15.

Portela A, Esteller M . Epigenetic modifications and human disease. Nat Biotechnol. 2010; 28(10):1057-68. DOI: 10.1038/nbt.1685. View

16.

Kumar V, Kato N, Urabe Y, Takahashi A, Muroyama R, Hosono N . Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet. 2011; 43(5):455-8. DOI: 10.1038/ng.809. View

17.

Chang K, Hao S, Liu C, Cheng M, Chang Y, Lee Y . Promoter polymorphisms of DNMT3B and the risk of head and neck squamous cell carcinoma in Taiwan: a case-control study. Oral Oncol. 2006; 43(4):345-51. DOI: 10.1016/j.oraloncology.2006.04.006. View

18.

Taberlay P, Jones P . DNA methylation and cancer. Prog Drug Res. 2010; 67:1-23. DOI: 10.1007/978-3-7643-8989-5_1. View

19.

Wu Y, Lin J . DNA methyltransferase 3B promoter polymorphism and its susceptibility to primary hepatocellular carcinoma in the Chinese Han nationality population: a case-control study. World J Gastroenterol. 2007; 13(45):6082-6. PMC: 4250895. DOI: 10.3748/wjg.v13.45.6082. View

20.

Lee S, Jeon H, Jang J, Park S, Lee G, Lee B . DNMT3B polymorphisms and risk of primary lung cancer. Carcinogenesis. 2004; 26(2):403-9. DOI: 10.1093/carcin/bgh307. View